Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report

Rebecca Pedersini1, Emanuela Vattemi1, Maria Rita Lusso1, Guido Mazzoleni2, Heinrich Ebner3, and Claudio Graiff1

1Division of Medical Oncology, 2Division of Pathology, and 3Division of Vascular and Thoracic Surgery, Central Hospital, Bolzano, Italy

ABSTRACT

Aims and background. Advanced chemorefractory epithelial thymic tumors are still a challenge in clinical oncology. A therapeutic approach targeting a key molecular pathway could be the ideal solution in a neoplasm that can overexpress epidermal growth factor receptor (EGFR) in the epithelial component.

Methods. A patient with metastatic heavily pretreated thymic carcinoma was evaluated for EGFR expression in the primary tumor.

Results. Strong EGFR expression was revealed by immunohistochemistry. The patient received erlotinib therapy but had obtained no response after four months of treatment.

Conclusion. This preliminary experience suggests that erlotinib may not be a useful therapeutic choice in advanced pretreated thymic carcinomas.

Key words: malignant thymoma, target therapy, EGFR, erlotinib.

Correspondence to: Dr Rebecca Pedersini, Oncology Department, Central Hospital Bolzano, L Böhler 5, 39100 Bolzano, Italy. Tel +39-0471-908572; fax +39-0471-908956; e-mail rebecca.pedersini@asbz.it

Received February 12, 2008; accepted May 28, 2008.